Nuvectis Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nuvectis Pharma, Inc. - overview
Established
2020
Location
Fort Lee, NJ, US
Primary Industry
Biotechnology
About
Based in New Jersey, US, and founded in 2020, Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. As of 2022, Ron Bentsur is the CEO of the company. In May 2021, Nuvectis Pharma, Inc.
raised USD 15. 3 million in Series A funding from Sixth Element Capital and other investors. The company is traded on the NASDAQ under the ticker symbol NVCT. The company is developing a pipeline that includes two drug candidates, such as NXP800, which is an oral small molecule HSF-1 pathway inhibitor, and NXP900, which is an oral small molecule SRC/YES1 kinase inhibitor.
Current Investors
Sixth Element Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.nuvectis.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.